The role of microbes in Crohn's disease

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 256-262

  Eckburg, Paul B ^a,b   Relman, David A ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLAMYDIA; CLINICAL FEATURE; COXIELLA; CROHN DISEASE; ENVIRONMENTAL FACTOR; ESCHERICHIA COLI; GENETIC PREDISPOSITION; HELICOBACTER PYLORI; HEREDITY; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INTESTINE EPITHELIUM; LISTERIA MONOCYTOGENES; MEASLES VIRUS; MICROORGANISM; MUCOSAL IMMUNITY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM PARATUBERCULOSIS; MYCOPLASMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SACCHAROMYCES CEREVISIAE; STREPTOCOCCUS; TECHNIQUE; YERSINIA PSEUDOTUBERCULOSIS;

CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL MUCOSA;

EID: 33846138032     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510385     Document Type: Review

References (88)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
2. Wen Z, Fiocchi C. Inflammatory bowel disease: autoimmune or immune-mediated pathogenesis? Clin Dev Immunol 2004; 11: 195-204.
3. Lindberg E, Tysk C, Andersson K, Jarnerot G. Smoking and inflammatory bowel disease. A case control study. Gut 1988; 29:352-7.
4. Binder V, Orholm M. Familial occurrence and inheritance studies in inflammatory bowel disease. Neth J Med 1996; 48:53-6.
5. Kleer CG, Appelman HD. Surgical pathology of Crohn's disease. Surg Clin North Am 2001; 81:13-30.
6. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8:10-5.
7. Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 2005;51(Suppl 1): 96-102.
8. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262-7.
9. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338:771-4.
10. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996; 26: 934-8.
11. Rath HC, Herfarth HH, Ikeda JS, et al. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98:945-53.
12. Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998; 66:5224-31.
13. Van Kruiningen HJ, Colombel JF, Cartun RW, et al. An in-depth study of Crohn's disease in two French families. Gastroenterology 1993; 104:351-60.
14. Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003; 124:1767-73.
15. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins: results of a nationwide study. Scand J Gastroenterol 2000;35:1075-81.
16. Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2: 693-6.
17. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. 1. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig Dis Sci 1984; 29:1073-9.
18. McFadden JJ, Butcher PD, Chiodini R, Hermon-Taylor J. Crohn's disease-isolated mycobacteria are identical to Mycobacterium paratuberculosis, as determined by DNA probes that distinguish between mycobacterial species. J Clin Microbiol 1987; 25:796-801.
19. Sanderson JD, Hermon-Taylor J. Mycobacterial diseases of the gut: some impact from molecular biology. Gut 1992; 33:145-7.
20. Sartor RB. Does Mycobacterium avium subspecies paratuberculosis cause Crohn's disease? Gut 2005; 54:896-8.
21. Yoshimura HH, Graham DY, Estes MK, Merkal RS. Investigation of association of mycobacteria with inflammatory bowel disease by nucleic acid hybridization. J Clin Microbiol 1987; 25:45-51.
22. Darfeuille-Michaud A, Boudeau J, Bulois P, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127: 412-21.
23. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Escherichia constrains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998; 115:1405-13.
24. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004; 127:80-93.
25. Graham DY, Yoshimura HH, Estes MK. DNA hybridization studies of the association of Pseudomonas maltophilia with inflammatory bowel diseases. J Lab Clin Med 1983; 101: 940-54.
26. Wei B, Huang T, Dalwadi H, Sutton CL, Bruckner D, Braun J. Pseudomonas fluorescens encodes the Crohn's disease-associated 12 sequence and T-cell superantigen. Infect Immun 2002; 70:6567-75.
27. Liu Y, van Kruiningen HJ, West AB, Cartun RW, Cortot A, Colombel JF. Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995; 108:1396-404.
28. Kangro HO, Chong SK, Hardiman A, Heath RB, Walker-Smith JA. A prospective study of viral and mycoplasma infections in chronic inflammatory bowel disease. Gastroenterology 1990; 98:549-53.
29. Schuller JL, Piket-van Ulsen J, Veeken IV, Michel MF, Stolz E. Antibodies against Chlamydia of lymphogranuloma-venereum type in Crohn's disease. Lancet 1979; 1:19-20.
30. Puspok A, Dejaco C, Oberhuber G, et al. Influence of Helicobacter pylori infection on the phenotype of Crohn's disease. Am J Gastroenterol 1999; 94:3239-44.
31. Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 1984; 87:888-94.
32. Main J, McKenzie H, Yeaman GR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297:1105-6.
33. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994; 344:508-10.
34. Smith MS, Wakefield AJ. Viral association with Crohn's disease. Ann Med 1993; 25:557-61.
35. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological and clinical entity. JAMA 1932; 99:1323-9.
36. Dalziel TK. Chronic interstitial enteritis. BMJ 1913; 2:1068.
37. Harris NB, Barletta RG. Mycobacterium avium subsp. paratuberculosis in veterinary medicine. Clin Microbiol Rev 2001; 14:489-512.
38. Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev 1989; 2: 90-117.
39. Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev Microbiol 2004; 58:329-63.
40. Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95: 725-9.
41. Parrish NM, Ko CG, Dick JD, Jones PB, Ellingson JL. Growth, Congo Red agar colony morphotypes and antibiotic susceptibility testing of Mycobacterium avium subspecies paratuberculosis. Clin Med Res 2004; 2:107-14.
42. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:481-7.
43. Eckburg PB, Bik EM, Bernstein CN, Sargent M, Purdom EA, Relman DA. Molecular analysis of the colonic mucosal microbiota in patients with Crohn's disease [abstract 416]. In: Program and abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America (San Francisco). Alexandria, VA: Infectious Diseases Society of America, 2005:11.
44. Kanagawa T. Bias and artifact in multitemplate polymerase chain reactions (PCR). J Biosci Bioeng 2003; 96:317-23.
45. Jaspers E, Overmann J. Ecological significance of microdiversity: identical 16S rRNA gene sequences can be found in bacteria with highly divergent genomes and ecophysiologies. Appl Environ Microbiol 2004; 70:4831-9.
46. Sansonetti PJ. War and peace at mucosal surfaces. Nat Rev Immunol 2004; 4:953-64.
47. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science 2005; 308:1635-8.
48. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68:3401-7.
49. Lay C, Rigottier-Gois L, Holmstrom K, et al. Colonic microbiota signatures across five northern European countries. Appl Environ Microbiol 2005; 71:4153-5.
50. Hayashi H, Sakamoto M, Benno Y. Fecal microbial diversity in a strict vegetarian as determined by molecular analysis and cultivation. Microbiol Immunol 2002; 46:819-31.
51. Tannock GW, Munro K, Bibiloni R, et al. Impact of consumption of oligosaccharide-containing biscuits on the fecal microbiota of humans. Appl Environ Microbiol 2004; 70: 2129-36.
52. Marshall JC. Gastrointestinal flora and its alterations in critical illness. Curr Opin Clin Nutr Metab Care 1999; 2:405-11.
53. Young VB, Schmidt TM. Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota. J Clin Microbiol 2004; 42:1203-6.
54. Holdeman LV, Good IJ, Moore WE. Human fecal flora: variation in bacterial composition within individuals and a possible effect of emotional stress. Appl Environ Microbiol 1976; 31:359-75.
55. Hopkins MJ, Sharp R, Macfarlane GT. Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 2001; 48:198-205.
56. Zoetendal EG, Akkermans AD, Akkermansvan Vliet WM, De Visser AGM, De Vos WM. The host genotype affects the bacterial community in the human gastrointestinal tract. Microbial Ecol Health Dis 2001; 13:129-34.
57. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002; 122:44-54.
58. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M, Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand J Gastroenterol 2002; 37:1034-11.
59. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006; 55:205-11.
60. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003; 52:237-42.
61. Spiegelman D, Whissell G, Greer CW. A survey of the methods for the characterization of microbial consortia and communities. Can J Microbiol 2005; 51:355-86.
62. Garcia-Lafuente A, Antolin M, Guarner F, Crespo E, Malagelada JR. Modulation of colonic barrier function by the composition of the commensal flora in the rat. Gut 2001; 48: 503-7.
63. Hermiston ML, Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995; 270:1203-7.
64. Bush TG, Savidge TC, Freeman TC, et al. Fulminant jejuno-ileitis following ablation of enteric glia in adult transgenic mice. Cell 1998; 93:189-201.
65. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996; 110: 1395-403.
66. Macpherson A, Khoo UY, Forgacs I, Philpott-Howard J, Bjaraason I. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996; 38:365-75.
67. Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004; 113:1296-306.
68. Arnott ID, Landers CJ, Nimmo EJ, et al. Seroreactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol 2004; 99:2376-84.
69. Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1999; 1:410-6.
70. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004; 36:471-5.
71. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004; 36:476-80.
72. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005;174:4453-60.
73. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004; 118:229-41.
74. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev 2005; 206:277-95.
75. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease?-the toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 2004; 53:987-92.
76. Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology 2004; 127:365-6.
77. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000; 68: 7010-7.
78. Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005; 307:734-8.
79. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003; 124:993-1000.
80. Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307:731-4.
81. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001; 411:599-603.
82. Ogura Y, Bonen DK, Inohara N, et al. A frame-shift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411:603-6.
83. Lesage S, Zouali H, Cezard JP, et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002; 70:845-57.
84. Newman B, Gu X, Wintle R, et al. A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenorypic expression of Crohn's disease. Gastroenterology 2005; 128:260-9.
85. Fredericks DN, Relman DA. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates. Clin Microbiol Rev 1996; 9:18-33.
86. Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000; 4:1-11.
87. Fukushima K, Yonezawa H, Fiocchi C. Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm Bowel Dis 2003; 9:290-301.
88. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10:445-56.